DOCSLIB.ORG

Ongoing and Planned Trials of Preventive Hiv/Aids Vaccines (May 2012)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ongoing and Planned Trials of Preventive Hiv/Aids Vaccines (May 2012) ONGOING AND PLANNED TRIALS OF PREVENTIVE HIV/AIDS VACCINES (MAY 2012) Vaccine Sponsor/Funder/ Number of Status / Expected Trial 1 Phase Start Date Vaccine(s) 3 Trial Site 2 Clade abbreviation 3 Developer 2 Participants Completion Phase IIb (safety and efficacy) US (Nashville, TN; Birmingham, AL; Los Angeles, CA; San Francisco, CA; Denver, CO; Orlando, FL; Atlanta, VRC-HIVDNA016-00-VP; GA; Chicago, IL; DNA VRC-HIVADV014-00-VP Bethesda, MD; Boston, Ongoing / Expected HVTN 505 Phase IIb June 2009 DAIDS, NIAID, VRC 2,200 A, B, C Ad5 Prime: VRC-HIVDNA016- MA; New York, NY; 2013 00-VP Rochester, NY; Cleveland, OH; Philadelphia, PA; Dallas, TX; Houston, TX; Annandale, VA; Seattle, WA) Phase II (safety, adherence, acceptability, feasibility) ANRS 149 September DNA GTU-MultiHIV B DNA and Planned / Expected Phase II ANRS France (Créteil) 105 B LIGHT 2012 Lipopeptide LIPO-5 vaccines December 2014 ALVAC-HIV (vCP1521) U.S. Army Medical Canarypox Priming With VaxGen RV 305 Phase II March 2012 Research and Thailand (Chon Buri) 162 Ongoing / June 2013 gp120 B/E (AIDSVAX B/E) gp120 Materiel Command Boosting JS7 plasmid DNA and MVA62B vaccine Peru (Lima), US Ongoing, fully enrolled administered as (1) DNA January DNA DAIDS, GeoVax Labs (Birmingham, AL; San / August 2012, long- HVTN 205 Phase IIa at months 0 and 2 and 299 B 2009 Inc. Francisco, CA; New York, term follow-up Aug MVA MVA at months 4 and 6 NY; Seattle, WA) 2014 or (2) MVA at months 0, 2 and 6 Phase I/II and Ib (safety, adherence, acceptability, feasibility) January Modified Vaccinia Karolinska Institutet, Planned / September HIVIS 06 Phase I/II MVA Tanzania 20 2012 Ankara SMl, WRAIR 2012 US (Chicago, IL; New York, NY; Nashville, TN; Ongoing / Expect to December HVTN 085 Phase Ib Ad5 VRC rAd5 HIV vaccine DAIDS, NIAID, VRC Philadelphia, PA; 90 A, B, C close to accrual August 2011 Rochester, NY; San 2012 Francisco, CA) VRC-HIVDNA016-00-VP clade B gag, pol, and nef, clade A env, clade DNA B env, clade C env HVTN 076 Phase Ib May 2011 DAIDS, NIAID, VRC US (Seattle) 45 A, B, C Ongoing Ad5 VRC-HIVADV014-00-VP clade B gag-pol, clade A env, clade B env, clade C env Single dose: VRC- Brazil (Sao Paulo), Peru Ongoing / Expect to HIVADV014-00-VP or (Iquitos, Barranco), close to enrollment January HVTN 084 Phase Ib Ad5 VRC-HIVADV054-00-VP DAIDS, HVTN, VRC Switzerland (Lausanne), 100 A, B, C March 2012, then 2011 (adenoviral vectors) US (Boston, MA; New participants in follow- Inserts: ADV014:clade B York, NY and Chicago, IL) up gag-pol; clades A, B, C env; ADV054: clade B gag-pol Prime: VRC-HIVDNA016- 00-VP (DNA vaccine) ; Boost VRC-HIVADV014- 00-VP (adenoviral Ongoing / Closed to January DNA vector) US (Boston, MA; Seattle, HVTN 082 Phase Ib DAIDS, NIAID, VRC 8 A, B, C enrollment, participants 2010 Inserts: ADV014:clade B WA; San Francisco, CA) Ad5 in follow-up gag-pol; clades A, B, C env; ADV016: clade B gag, pol, and nef, clades A, B and C env October vaccinia virus NYVAC-B; VRC- EuroVacc, HVTN, HVTN 078 Phase Ib Switzerland (Lausanne) 80 A, B, C Ongoing 2009 Ad5 HIVADV038-00-VP NIAID, VRC Recombinant Adenoviral Subtype 35 (rAd35) and Subtype 5 (rAd5) HIV-1 Vaccines When Given as a US (Birmingham, AL; San Heterologous Prime- Francisco, CA; Atlanta, Ongoing / Closed to January Boost Regimen or as HVTN 077 Phase Ib DNA/Ad35 DAIDS, NIAID, VRC GA; Boston,MA; New 192 A enrollment, participants 2007 Boosts to a Recombinant York, NY; Rochester, NY; in follow-up DNA Vaccine in Healthy, Seattle, WA) Ad5-Naïve and Ad5- Exposed (VRC- HIVDNA044-00-VP;VRC- HIVADV027-00-VP;VRC- HIVADV038-00-VP) Phase I (safety, adherence, acceptability, feasibility) Targeted MAVEN Ad26 Phase I start date of Ad26/MVA mosaic MHRP Thailand, Uganda, US 120 Planned (RV 307) 2014 MVA DNA Targeted vaccinia virus DNA/NYVAC/Tenofovir HVTN 095 Phase I start date HVTN, MTN TBD 144 Planned gel/Truvada Q4 2012 Tenofovir gel Truvada Targeted DNA HVTN 092 Phase I start date DNA schedule/NYVAC HVTN TBD 204 Planned Q3 2012 vaccinia virus Targeted gp120 RV 306 Phase I start date of AIDSVAX /ALVAC B/E MHRP Thailand 460 Planned Q3 2012 Canarypox Targeted RV 328 Phase I start date of gp120 AIDSVAX B/E MHRP Thailand 40 Planned Q3 2012 Targeted DNA HVTN 087 Phase I start date of IL12 DNA/IL-12/VSV NIAID US 100 Planned Q2 2012 VSV Targeted DNA DNA/NYVAC/AIDSVAX HVTN 096 Phase I start date of vaccinia virus HVTN US 96 Planned B/E Q2 2012 gp120 GEO-D03 plasmid DNA B, DNA Planned / Expect to and MVA62B vaccine US (Boston, MA; Targeted co- open April 2012 and DNA administered as DNA at DAIDS, GeoVax Labs Rochester, NY; San HVTN 094 Phase I start date of 48 expresses expect to close to months 0 and 2 and Inc., NIAID, Francisco, CA; Q2 2012 MVA GM-CSF accrual November MVA at months 4, 6, and Birmingham, AL) adjuvant 2012 8 Sumagen, Living Killed-Whole Killed-Whole HIV-1 24 HIV-positive SAV-CT01 Phase I March 2012 Hope Clinical US (Los Angeles, CA) Ongoing / March 2013 Vaccine (SAV001-H) participants HIV Foundation European January Ongoing / January EuroNeut41 Phase I gp41 EN41-FPA2 HIV Vaccine Commission; UK (Surrey) 48 2012 2013 PX'Therapeutics Multiantigen HIV (HIV- MAG) Plasmid DNA (pDNA) Vaccine Co- Rwanda (Kigali); Kenya administered With IAVI, Ichor, Profectus and Uganda sites in 2012 December DNA Recombinant Human IL- and three clinical IAVI B004 Phase I pending approvals 75 Ongoing / April 2013 2011 12 pDNA (GENEVAX® IL- research partners in IL2 12) Followed or Africa Preceded by Recombinant Ad35- GRIN/ENV HIV Vaccine SAAVI DNA-C2 prime and SAAVI MVA-C boost, with and without concurrent Novartis November DNA subtype C gp140/MF59 DAIDS, NIAID, South Africa (Klerksdorp; HVTN 086 Phase I 184 C Ongoing 2011 gp140 boost; SAAVI MVA-C Novartis, SAAVI Soweto; Cape Town) with concurrent or subsequent Novartis subtype C gp140/MF59 vaccine. SGUL, the Wellcome Trust under Grand November United Kingdom (London, Ongoing / November Mucovac2 Phase I Gp140 CN54gp140 Challenges in Global 36 C 2011 York) 2012 Health Initiative, UKHVC US (Boston, NY; October Novartis Sub C gp140 Rochester,NY), South HVTN 073E Phase I gp 140 DAIDS, NIAID, SAAVI 36 C Ongoing 2011 with MF59 Africa (Cape Town, Soweto) US (Atlanta, GA; October VSV IN HIV gag vaccine Nashville, TN ; HVTN 090 Phase I VSV DAIDS, NIAID 60 B Ongoing 2011 (rVSVN4CT1gag1) Philadelphia, PA; San Francisco, CA) Clade B HIV-1 Tat HIV-1 Tat/delta-V2 Env Istituto Superiore di protein; combined vaccine Sanita in cooperation ISS P-002 September Italy (Modena, Monza, clade C Recruiting / February Phase I Tat HIV-1 delta-V2 Env with Novartis 50 2011 Rome) HIV-1 2014 vaccine Vaccines & delta-V2 HIV-1 Tat vaccine Diagnostics Env protein DNA Env EDTCP, Imperial ABC, gag College, INS, MHRP, Mozambique AB, Rtmut DNA Prime: HIVIS-DNA Muhimbili University (Maputo),Tanzania Ongoing / December TaMoVac I Phase I August 2011 240 B, rev B; Boost: MVA- CMDR of Health and Allied (Dar es Salaam and 2012 MVA MVA Env Sciences, SMI, Mbeya) E, gag A, University of Munich pol A US (Birmingham, AL; Novartis Sub C gp140 Ongoing, participants HVTN 088 Phase I August 2011 gp 140 DAIDS, NIAID Nashville, TN; Rochester, 40 C with MF59 in follow-up NY; Seattle, WA Novartis Sub C gp140 HVTN 073E DNA with MF59 US (Boston, NY; (Extension Adjuvant, as a Boost Rochester, NY), South Phase I August 2011 MVA DAIDS, NIAID, SAAVI 36 C Ongoing HVTN 073E / Following SAAVI DNA-C2 Africa (Cape Town, SAAVI 102) gp140 Vaccine and SAAVI Soweto) MVA-C Vaccine CN54gp140- hsp70 CN54gp140 Ongoing / February Conjugate Phase I July 2011 gp140 glycoprotein-hsp70 EU, SGUL UK (London) 8 C 2012 Vaccine conjugate vaccine (TL01) DNA VRC-HIVADV014-00-VP VRC 016 Phase I June 2011 and VRC-HIVDNA016-00- NIAID, VRC US (Bethesda, MD) 24 A, B, C Ongoing / July 2014 Ad5 VP Ad26.ENVA.01 and AD35ENV (adenoviral vectors) given in 80 for HVTN Ongoing / Closed to Ad26 heterologous or South Africa (Klerksdorp; HVTN 091 Phase I May 2011 IAVI (SA) sites; 212 A enrollment, participants homolgous prime-boost Soweto; Cape Town) Ad35 for entire study in follow-up doses inserts: Clade A env gp140 February DNA Ad35 investigational HIV Ongoing / November IAVI B002 Phase I GSK, IAVI Kenya, Uganda, Zambia 140 2011 Ad35 vaccine 2012 October Ad5 rAD35 env A/rAd5 env HVTN 083 Phase I VRC US 180 Ongoing/ In follow-up 2010 Ad35 A/B pSG2.HIVconsv DNA, October DNA Ongoing / October HIV-CORE002 Phase I ChAdV63.HIVconsv and University of Oxford UK (Oxford) 32 2010 2012 MVA MVA.HIVconsv rAd35:(VRC-HIVADV027- 00-VP); rAd5: (VRC- US (Birmingham, AL; San HIVADV038-00-VP); rAd5: Francisco, CA; Atlanta, Ongoing / Closed to October Ad5 HVTN 083 Phase I (VRC-HIVADV052-00-VP) DAIDS, NIAID, VRC GA; Boston, MA; New 180 A, B enrollment, participants 2010 Ad35 Inserts: rAD35: env clade York, NY; Rochester, NY; in follow- up A; rAD5(038): env clade Nashville, TN) A; rAD5(052) env clade B Beth Israel Kenya (Kangemi), Deaconess Medical Recombinant Rwanda (Kigali), South Center, Brigham and IAVI B003 October Ad26 Adenovirus HIV-1 Africa (Cape Town, Ongoing, not recruiting Phase I Women's Hospital, 217 (52 at BWH) A (IPCAVD 004) 2010 Vaccine, Ad26.ENVA.01 Johannesburg, & / September 2012 Ad35 Crucell, IAVI, and Ad35-ENV Klerksdorp), US (Boston, IPCAVD, HVTN, NIAID, MA) Ragon Institute Beth Israel Deaconess Medical Ad26.ENVA.0 Recombinant September Center, Brigham and Ongoing, not recruiting 1 (IPCAVD Phase I Ad26 Adenovirus HIV-1 US (Boston, MA) 24 A 2010 Women's Hospital, / November 2012 003) Vaccine, Ad26.ENVA.01 Crucell, IPCAVD, NIAID Prime: PENNVAX-G DNA (ENV & GAG) Administered by September Intramuscular Biojector Ongoing / Not yet 2010, will Kenya (Kericho), Uganda DNA 2000 or CELLECTRA A, B, C, open to recruitment at RV 262 Phase I start in MHRP, NIAID (Kampala), Tanzania 92 Intramuscular D, E African sites, US fully Africa in Q2 MVA (Mbeya) Electroporation Device enrolled 2012 Boost: MVA-CMDR (HIV- 1 CM235 ENV/CM240 GAG/POL) JS7 plasmid DNA and GeoVax MVA62B vaccine US (Atlanta, GA; Therapeutic DNA Ongoing, recruiting/ Phase I June 2010 administered as DNA at GeoVax Labs, Inc.
Load more

Recommended publications
  • The CAB Bulletin HIV Vaccines and the Community
    The CAB Bulletin HIV Vaccines and the Community Planning for PrEP My First Time By Genevieve Meyer, HVTN Community Education Unit By Dino Martino, On November 23rd, 2010, the results of the iPrEx study were released. The Orlando, FL CAB member. 2,499-person study demonstrated that a daily dose of oral Truvada®, (a With nervous excitement I accepted combination of two antiretroviral medications, emtricitabine and tenofovir) could the offer to attend my first HVTN reduce new infections of HIV in gay men, transwomen and other men who have conference. As a member of the sex with men (MSM) by an average of 43.8%. The HVTN salutes the sponsors, newly formed CAB in Orlando, this study team, and volunteers in the 11 sites throughout Brazil, Ecuador, Peru, South Africa, Thailand and the United States who contributed to this study’s success. was another “first time” opportu- nity in a series of events that I have The results of the iPrEx study have added increased vigor to the HVTN’s search had the pleasure to be a part of in for a safe and effective HIV vaccine. One central question being asked at the HVTN support of the work of the HVTN. right now is what these results mean for participants in HVTN 505, a study which is also enrolling MSM and transwomen who are at risk of contracting HIV. As a pharmacist for nearly two de- cades, scientific conferences are not The Network has set up a working group to solicit feedback from community new to me; still, each one brings stakeholders about possible changes to HVTN 505 based on the iPrEx results.
    [Show full text]
  • Antibody Fc Effector Functions and Igg3 Associate with Decreased HIV-1 Risk
    RESEARCH ARTICLE The Journal of Clinical Investigation Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk Scott D. Neidich,1 Youyi Fong,2,3,4 Shuying S. Li,2,3 Daniel E. Geraghty,5 Brian D. Williamson,4 William Chad Young,2 Derrick Goodman,1 Kelly E. Seaton,1 Xiaoying Shen,1 Sheetal Sawant,1 Lu Zhang,1 Allan C. deCamp,2 Bryan S. Blette,6 Mengshu Shao,2 Nicole L. Yates,1 Frederick Feely,1 Chul-Woo Pyo,3 Guido Ferrari,1,7,8 HVTN 505 Team,9 Ian Frank,10 Shelly T. Karuna,3 Edith M. Swann,11 John R. Mascola,12 Barney S. Graham,12 Scott M. Hammer,13 Magdalena E. Sobieszczyk,13 Lawrence Corey,3 Holly E. Janes,2,3,4 M. Juliana McElrath,3 Raphael Gottardo,2,3 Peter B. Gilbert,2,3,4 and Georgia D. Tomaras1,7,8,14 1Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA. 2Statistical Center for HIV/AIDS Research and Prevention, 3Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 4Department of Biostatistics, University of Washington, Seattle, Washington, USA. 5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 6Department of Biostatistics, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA. 7Department of Surgery and 8Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA. 9The HVTN 505 Team is detailed in the Supplemental Acknowledgments. 10Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia Pennsylvania, USA. 11Division of AIDS and 12Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
    [Show full text]
  • Safety and Immunogenicity of a Recombinant Adenovirus Serotype
    C S & lini ID ca A l f R o e l s Fuchs et al., J AIDS Clin Res 2015, 6:5 a e n a r r u c o h J AIDS & Clinical http://dx.doi.org/10.4172/2155-6113.1000461 ISSN: 2155-6113 Research Research Article Open Access Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals Jonathan D Fuchs1,2,*, Pierre-Alexandre Bart3, Nicole Frahm4, Cecilia Morgan4, Peter B Gilbert4, Nidhi Kochar4, Stephen C DeRosa4, Georgia D Tomaras5, Theresa M Wagner1, Lindsey R Baden6, Beryl A Koblin7, Nadine G Rouphael8, Spyros A Kalams9, Michael C Keefer10, Paul A Goepfert11, Magdalena E Sobieszczyk12, Kenneth H Mayer13, Edith Swann14, Hua-Xin Liao5, Barton F Haynes5, Barney S Graham15 and M Juliana McElrath4 for the NIAID HIV Vaccine Trials Network 1Population Health Division, San Francisco Department of Public Health, San Francisco, CA, USA 2Department of Medicine, University of California, San Francisco, San Francisco, USA 3Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland 4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 5Human Vaccine Institute, Duke University, Durham, NC, USA 6Division of Infectious Disease, Brigham and Women’s Hospital, Boston, MA, USA 7Laboratory of Infectious Disease Prevention, New York Blood Center, New York, NY, USA 8The Hope Clinic, Division of Infectious Diseases, Emory University, Atlanta, GA, USA 9Infectious Diseases Division, Vanderbilt University School of Medicine, Nashville,
    [Show full text]
  • (Sexpro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States
    Title: Development and Validation of the Personalized Sexual Health Promotion (SexPro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States. Authors Title Email Site Hyman Scott [email protected] Bridge HIV, San Francisco Department of (corresponding) Public Health, San Francisco, California Eric Vittinghoff [email protected] University of California, San Francisco, San Francisco, CA Risha Irvin [email protected] John’s Hopkins School of Medicine, Baltimore, Maryland Albert Liu [email protected] Bridge HIV, San Francisco Department of Public Health, San Francisco, CA LaRon Nelson [email protected] University of Rochester. Rochester, New er.edu York Carlos Del Rio [email protected] Emory University, Atlanta, Georgia Manya Magnus [email protected] George Washington University, Washington, District of Columbia Sharon [email protected] Columbia University, New York, New Mannheimer York Sheldon Fields [email protected] Charles Drew School of Medicine, Los Angeles, California Irene Kuo [email protected] George Washington University, Washington, District of Columbia Steve Shoptow [email protected] University of California, Los Angeles, California Beatrice [email protected] Instituto de Pesquisa Clinica Evandro Grinsztejn Chagas (IPEC), Rio de Janeiro, Brazil Jorge Sanchez [email protected] Asociacion Civil Impacta Salud y Educacion, Lima, Peru Steven [email protected] Fred Hutchinson Cancer Research Center, Wakefield Seattle, Washington Jonathan Fuchs [email protected]
    [Show full text]
  • Advancing Toward HIV-1 Vaccine Efficacy Through the Intersections of Immune Correlates
    Vaccines 2014, 2, 15-35; doi:10.3390/vaccines2010015 OPEN ACCESS vaccines ISSN 2076-393X www.mdpi.com/journal/vaccines Review Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates Georgia D. Tomaras 1,* and Barton F. Haynes 2 1. Departments of Surgery, Immunology, and Molecular Genetics and Microbiology, Duke Human Vaccine Institute, Durham, NC 27710, USA 2. Departments of Medicine and Immunology, Duke Human Vaccine Institute, Durham, NC 27710, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-919-681-5598; Fax: +1-919-684-5230. Received: 29 October 2013; in revised form: 29 October 2013 / Accepted: 9 December 2013 / Published: 27 December 2013 Abstract: Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine clinical trials have provided hypotheses regarding the mechanisms of induction of protective immunity to HIV-1. To date, there have been six HIV-1 vaccine efficacy trials (VAX003, Vaxgen, Inc., San Francisco, CA, USA), VAX004 (Vaxgen, Inc.), HIV-1 Vaccine Trials Network (HVTN) 502 (Step), HVTN 503 (Phambili), RV144 (sponsored by the U.S. Military HIV Research Program, MHRP) and HVTN 505). Cellular, humoral, host genetic and virus sieve analyses of these human clinical trials each can provide information that may point to potentially protective mechanisms for vaccine-induced immunity. Critical to staying on the path toward development of an efficacious vaccine is utilizing information from previous human and non-human primate studies in concert with new discoveries of basic HIV-1 host-virus interactions. One way that past discoveries from correlate analyses can lead to novel inventions or new pathways toward vaccine efficacy is to examine the intersections where different components of the correlate analyses overlap (e.g., virus sieve analysis combined with humoral correlates) that can point to mechanistic hypotheses.
    [Show full text]
  • The CAB Bulletin HIV Vaccines and the Community in This Issue: S
    The CAB Bulletin HIV Vaccines and the Community In this Issue: S. Africa CAB Retreat 2 CROI, GCAB Elections 3 Full Group Meeting 4-5 Honors & Awards 6-7 Calls & Announcements 8 From Unique Paths, Hope Takes Action— The Community Education Unit Reflections on the U.S./Swiss CAB Retreat Welcomes Niles Eaton By Reese Aaron Isbell, San Francisco CAB member Those who attended the Full Group Editor’s note on the CAB Retreats: From April 9-11, 2010 the CEU conducted a Meeting were introduced to the new U.S./Swiss CAB Retreat in Seattle, Washington. It was similar in format to the manager of the HVTN Community South African CAB retreat (see article by Siyabonga Nzimande in this issue): a Education Unit (CEU), Niles Eaton. train-the-trainer approach where CAB members worked with staff from the CEU to Niles may be new to the CEU but he present on topics such as an Introduction to Vaccinology, Introduction to Research is certainly not new to community Ethics, How to Read a Protocol, Vaccine-Induced Seropositivity, and many more. education or to the HVTN. Niles has Originally scheduled for June, 2010, the Latin American and Caribbean CAB spent the last seven years as a Clinical Retreat will take place in late Trials Manager and is incredibly 2010 or early 2011. “We all had two important knowledgeable about site operations We arrived separately and things in common: we were and structures. we ranged in age, race, Prior to joining creed and color. We were volunteers, and we were the HVTN, Niles gay, bi, straight, single, part of a world-wide effort to spent seven married (legally and eradicate HIV/AIDS.” years as a study one-day-soon-to-be).
    [Show full text]
  • HVTN CAB Bulletin HIV Vaccines and the Community
    HVTN CAB Bulletin HIV Vaccines and the Community In this Issue: Cape Town CAB Member Gets Published 2 HVAD Around the World 3 HVTN Conference Highlights 4 Welcome Jim Maynard! The Global CAB Welcomes David The Community Galetta as New Co-Chair Education Unit By Carrie Schonwald, Community Education Unit welcomed Jim Maynard as the new Associate Director We would like to announce the election of for Community Reverend David Galetta as International Development GCAB Co-Chair. David is currently the and Recruitment CAB Chairperson of the Desmond Tutu (overseeing both HIV Foundation in Cape Town, South Jim Maynard, Associ- ate Director for Com- Community Education Africa, where he has been a CAB member munity Development and Communications) since 2004. Rev. Galetta graduated with a & Recruitment. on May 16. Prior to the Post Graduate Diploma in International HVTN, Jim spent over Research Ethics from the University of Cape David Galetta, new international GCAB 12 years at the Fenway Institute (part Town in 2009 and serves on their Human Co-Chair. of Fenway Health) where he served as Sciences Research Ethics Committee as the Associate Director for Community …continues on page 7 Engagement. Jim brings a wealth of knowledge and experience gained during his years working with HVTN trials HVTN 505 Expands in Size and Scope as well as the HIV Prevention Trials Network (HPTN), the Microbicide Trials By Rick Church, Rich Trevino, Coco Alinsug, Jason Roberts (Community Network (MTN) and the Adolescent Trials members of the HVTN 505 protocol team) and Gail Broder, HVTN Community Network (ATN). His team leadership, Education Unit site perspective, depth of experience, and relentlessly positive energy will be a welcome addition the Core team.
    [Show full text]
  • Intentions to Use Pre-‐Exposure Prophylaxis Among Current Phase
    Intentions to use pre-exposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants Jonathan D. Fuchs, MD, MPH,1,2 Magdalena E. Sobieszczyk, MD, MPH,3 Tamra Madenwald, MA, MPH,4 Doug Grove,5 Shelly T. Karuna, MD,4 Michele Andrasik, PhD,4 Adam Sherwat, MD,6 Gail Broder,4 Kenneth Mayer, MD,7 Beryl Koblin, PhD,8 and Scott Hammer, MD3 ; HVTN 505 Protocol Team 1San Francisco Department of Public Health 2Department of Medicine, University of California, San Francisco 3Dept. of Medicine, Division of Infectious Diseases, Columbia University College of Physicians and Surgeons 4HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center 5Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center 6National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 7 Fenway Health and the Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School 8Laboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute, New York Blood Center Correspondence and request for reprints: Jonathan Fuchs, MD, MPH, San Francisco Department of Public Health, 25 Van Ness Ave. Suite 100, San Francisco, CA 94102, Email: tel. (415) 437-7409, fax (415) 431-7029; email: [email protected] Preliminary analyses were presented at AIDS Vaccine 2011, Bangkok, Thailand Conflicts of Interest and Source of Funding: The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases (AI068614AI068635) which supports TM, DG, SK, MA, and GB. JF is supported under a Division of AIDS CTU award (UO1AI069496); MS and SH are supported under CTU and CTSA awards (UO1AI69470, UL1RR024156); KM is supported under CTU awards (UM1AI069480-05 and UO1AI069412) and unrestricted research grant support from Gilead Sciences, Inc.
    [Show full text]
  • The HVTN: Strategic Accomplishments of the First Decade and Beyond Tracey Day, Cecilia Morgan, Adi Ferrara, and Jim Kublin
    a Publication of the HIV Vaccine Trials Network VOLUME 3, ISSUE 2 | MARCH, 2012 Welcome to a new edition of the Our featured article in this issue is a HVTNews, the newsletter of the HIV look back at the Network’s achieve- Vaccine Trials Network. Our newslet- ments in 12 years of operation, and ter’s mission is to provide timely up- the impact it had on the HIV vaccine dates on the science of HIV vaccines, field. and the science of the HVTN. To that end, this issue features discussions that The search for an HIV vaccine is as include innate immunity studies at relevant and urgent today as it was at the HVTN, the possible impact of the the outset of the epidemic. We hope RV144 Correlates Analyses on future this issue gives you a glimpse of the vaccine trials, and the Network’s myriad ways in which the HVTN ongoing commitment to its study par- pursues our ultimate goal -- eradica- ticipants via our VISP testing service. tion with vaccination. Post RV144 Selection of gp120 [p. 8]. Figure of HIV-1 gp120 Env protein (red), bound to CD4 (yellow) and 17b antibody (blue) provided by Jonathan Stuckey, Vaccine Research Center, NIAID, NIH. The HVTN: Strategic Accomplishments of the First Decade and Beyond Tracey Day, Cecilia Morgan, Adi Ferrara, and Jim Kublin The development of an effective HIV Streamlined Protocol has been streamlining the protocol vaccine is one of humanity’s greatest Development Process development and implementation scientific challenges. In acknowledg- process. This has been achieved largely ing that the path to an effective HIV Before a clinical trial can begin, a through efforts to bring stakeholders vaccine will likely require numerous trial protocol outlining the protocol’s to the table at the appropriate time iterative steps, the HVTN has aimed objectives, target population, and con- and ensure that all support opera- to improve the process of designing, duct must be approved.
    [Show full text]
  • 2012 NIAID Jordan Report
    THE JORDAN REPORT ACCELERATED DEVELOPMENT OF VACCINES 2012 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases Images on cover, from the top: Courtesy of the US Centers for Disease Control and Prevention; istock.com; Courtesy of the National Library of Medicine; Courtesy of MedImmune THE JORDAN REPORT ACCELERATED DEVELOPMENT OF VACCINES 2012 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases NIH Publication No. 11-7778 January 2012 www.niaid.nih.gov ADDITIONAL RESOURCES National Institute of Allergy and Infectious Diseases, www.niaid.nih.gov Vaccines.gov: your best shot at good health, www.vaccines.gov Centers for Disease Control and Prevention: Immunization Schedules, www.cdc.gov/vaccines/recs/schedules/ Table of Contents INTRODUCTION VACCINE UPDATES Foreword by Anthony S. Fauci, M.D. ......................................... 3 Dengue M. Cristina Cassetti, Ph.D. .......................................................... 95 Tribute by Carole A. Heilman, Ph.D. ......................................... 5 HIGHLIGHT BOX Vaccine Against Chikungunya Virus in Development EXPERT ARTICLES Gary J. Nabel, M.D., Ph.D. and Ken Pekoc ......................... 97 Vaccinomics and Personalized Vaccinology Severe Acute Respiratory Syndrome Gregory A. Poland, M.D., Inna G. Ovsyannikova, Ph.D. and Frederick J. Cassels, Ph.D. ............................................................ 98 Robert M. Jacobson, M.D. .............................................................11 HIGHLIGHT BOX Sex Differences in Immune Responses to Vaccines Vaccine Delivery Technologies Col. Renata J. M. Engler, M.D. and Mary M. Klote, M.D. ....... 19 Martin H. Crumrine, Ph.D. ................................................. 105 Immunization and Pregnancy West Nile Virus Flor M. Munoz, M.D. .................................................................. 27 Patricia M. Repik, Ph.D.
    [Show full text]
  • Lessons Drawn from Recent HIV Vaccine Efficacy Trials
    SUPPLEMENT ARTICLE Lessons Drawn From Recent HIV Vaccine Efficacy Trials Jonathan D. Fuchs, MD, MPH,*† Magda E. Sobieszczyk, MD, MPH,§ Scott M. Hammer, MD,§ and Susan P. Buchbinder, MD*†‡ has not delivered one. A recently completed vaccine efficacy Abstract: A safe and effective HIV vaccine is needed to curtail the trial has inspired new hope that an HIV vaccine is US and global epidemics. However, the search for one has been achievable. Here we describe how the results from these elusive despite more than 25 years of focused research. Results from large clinical studies, some unexpected, are driving vaccine the RV144 Thai efficacy trial have renewed hope that a vaccine may discovery. We also outline important lessons about data protect against HIV acquisition. We can draw several scientific and analysis, dissemination, and recruitment of communities operational lessons from RV144 and other recent tests-of-concept at risk. efficacy trials. Here we describe how trial results, some unexpected, highlight the fundamental role these clinical studies play in HIV vaccine discovery. These trials also teach us that transparency in data HIV VACCINE EFFICACY TRIALS TO DATE analysis and results dissemination can yield substantial rewards and Since the first gp160 vaccine entered clinical testing in that efforts to engage communities, particularly those most heavily 1987, more than 150 trials of different vaccine candidates have affected by the epidemic, are needed to augment research literacy and been conducted.2 These trials reflect 3 distinct waves of trial recruitment. Future efficacy trial designs may incorporate novel, vaccine development, including approaches designed to elicit partially effective prevention strategies.
    [Show full text]
  • The Hvtnews Jim Kublin, Executive Director, HVTN
    a Publication of the HIV Vaccine Trials Network VOLUME 3, ISSUE 1 | SEPTEMBER, 2011 Welcome to the HVTNews Jim Kublin, Executive Director, HVTN Welcome to the HVTNews. With this immune system’s response to it grows, the edition, we would like to welcome new au- Network and its partners are developing diences and reintroduce our newsletter. In vaccine candidates that elicit promising im- this and future editions we will clarify why mune responses, with new vectors, proteins, HIV vaccine research in humans provides inserts, and new vaccine delivery mecha- critical momentum for the discovery and nisms; an important scientific milestone in development of effective vaccines. Upcom- our trials this past year was the use of elec- ing newsletter topics include monoclonal troporation of DNA plasmids, which nearly antibodies for prevention, electroporation, doubled the detectable immune response to efficacy trial capacity building, immu- the study’s vaccine candidate. notherapy, and community engagement. We will highlight the management of the Though the promising results of the latest Network’s many multilateral collaborations biomedical prevention trials are great news, Photo by Sarah Stefana Smith and our outstanding clinical sites that work the search for a vaccine is as relevant and Exploring Barriers: Participation of Male-to-Female Transgender Persons in HIV Vaccine Trials [p.16] in service to our mission. We are focused on urgent today as it was at the outset of the the dynamic field of combination preven- epidemic. Several factors must be consid- tion and the role of vaccine development ered in the context of an effective bio- activism and innovation the field deserves, plays and deployment in control of the HIV medical prevention regimen -- compliance, a major role in the ultimate control of this pan- pandemic.
    [Show full text]